Enormous high-grade carcinoma arising from a pleomorphic adenoma in the parotid gland: A case report

腮腺多形性腺瘤衍生的巨大高级别癌:病例报告

阅读:1

Abstract

INTRODUCTION: Pleomorphic adenomas can undergo malignant transformation into carcinoma ex pleomorphic adenoma (CXPA). CXPA is challenging to diagnose due to its resemblance to benign tumors. Surgical excision is the primary treatment, with adjuvant radiotherapy recommended for high-risk cases. Despite the aggressive nature of CXPA, extensive surgery may not always be feasible, especially in cases with contraindications for neck dissection. PRESENTATION OF CASE: A 69-year-old female with a 20-year history of a slowly growing buccal mass presented with rapid enlargement over the last four months. Imaging and biopsy confirmed high-grade CXPA, and surgery was performed with careful dissection to preserve facial nerve function. The tumor measured 24 × 18 × 15 cm, and no perineural or lymphovascular invasion was detected. The patient received adjuvant radiotherapy and remained disease-free at 12 months, with preserved facial nerve function. DISCUSSION: This case highlights the challenges of managing large CXPA tumors, particularly in preserving nerve function during surgery. The absence of perineural invasion in histological findings suggested a favorable prognosis, and postoperative radiotherapy significantly reduced the recurrence risk. While elective neck dissection is generally indicated in high-grade CXPA, it was contraindicated in this patient due to her medical condition. CONCLUSION: CXPA, despite its aggressive nature, can often be managed without extensive resection or nerve sacrifice. In cases where neck dissection is not feasible, radiotherapy can be an effective treatment. Future research into the genetic basis and targeted therapies for CXPA is essential to enhance personalized treatment strategies and improve outcomes for patients with this complex malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。